Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin A Walter

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
Cancer|March 13, 2009
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trialFabienne Iten, Beat Muller, Christian Schindler, et al.
World Journal of Surgery|April 24, 2019
Association of Surgical Volume and Quality Management in Thyroid Surgery: A Two-Nation Multicenter StudyDominik A Jakob, Philipp Riss, Christian Scheuba, et al.
Cancer|March 23, 2011
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomasSimona Grozinsky-Glasberg, Dganit Barak, Merav Fraenkel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 11, 2012
Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspectiveFranziska Walter, Timothy Cloughesy, Martin A Walter, et al.
American Journal of Nuclear Medicine and Molecular Imaging|July 26, 2018
Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparisonOlivier Rager, Stephanie A Lee-Felker, Claire Tabouret-Viaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersAnna Imhof, Philippe Brunner, Nicolas Marincek, et al.
Nature Communications|November 13, 2023
The Imageable GenomePablo Jané, Xiaoying Xu, Vincent Taelman, et al.
BMJ (Clinical Research Ed.)|February 21, 2007
Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trialsMartin A Walter, Matthias Briel, Mirjam Christ-Crain, et al.
Nature Communications|December 31, 2024
The Theranostic GenomeXiaoying Xu, Pablo Jané, Vincent Taelman, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Cancer|March 13, 2009
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trialFabienne Iten, Beat Muller, Christian Schindler, et al.
World Journal of Surgery|April 24, 2019
Association of Surgical Volume and Quality Management in Thyroid Surgery: A Two-Nation Multicenter StudyDominik A Jakob, Philipp Riss, Christian Scheuba, et al.
Cancer|March 23, 2011
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomasSimona Grozinsky-Glasberg, Dganit Barak, Merav Fraenkel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 11, 2012
Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspectiveFranziska Walter, Timothy Cloughesy, Martin A Walter, et al.
American Journal of Nuclear Medicine and Molecular Imaging|July 26, 2018
Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparisonOlivier Rager, Stephanie A Lee-Felker, Claire Tabouret-Viaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersAnna Imhof, Philippe Brunner, Nicolas Marincek, et al.
Nature Communications|November 13, 2023
The Imageable GenomePablo Jané, Xiaoying Xu, Vincent Taelman, et al.
BMJ (Clinical Research Ed.)|February 21, 2007
Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trialsMartin A Walter, Matthias Briel, Mirjam Christ-Crain, et al.
Nature Communications|December 31, 2024
The Theranostic GenomeXiaoying Xu, Pablo Jané, Vincent Taelman, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Pageof 8